# Trade Mark Journal No.2026/015 10 April 2026

## WO0000001894975 (5,44)

Office of origin: Switzerland

Date of International Registration:10 October 2025
Date of designation in the UK: 10 October 2025

The cross in the trademark shall be reproduced neither in white on a red background nor in red on a white background; it will also not be reproduced in any other color likely to cause confusion with the Swiss Federal Cross or the emblem of the Red Cross

International priority date claimed: 14 April 2025 (Switzerland) (831333)

Class 5
  Pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immunological disorders; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of graft versus host disorder (GVHD); pharmaceutical preparations for the treatment of hematological disorders; pharmaceutical preparations for the treatment of hypophosphatemia disorders; pharmaceutical preparations for the treatment of myeloproliferative disorders; pharmaceutical preparations for the treatment of skeletal or chondrocyte disorders; pharmaceutical preparations for the treatment of dermatological disorders; pharmaceutical preparations for the treatment of fibrotic disorders; pharmaceutical preparations for the treatment of auto-immune disorders.
Class 44
  Providing medical information via a website; Providing medical information to healthcare providers and patients relating to oncological, viral, hematological, auto-immune, graft versus host, inflammatory, metabolic, myeloproliferative, skeletal or chondrocyte and dermatological disorders.

Incyte Holdings Corporation

Representative: Page, White & Farrer Limited, Bedford House, John Street London WC1N 2BF UNITED KINGDOM